ACE‑031 (Ramatercept)
- Name: ACE‑031
- Synonyms: Ramatercept, ActRIIB‑IgG1 Fc fusion protein
- CAS Number: 1621169‑52‑5
- Quantity: Typically supplied in lyophilised vials for research use
- Formulation: Recombinant fusion protein
Key Features
- Purity: ≥ 95–98% (HPLC‑verified, depending on supplier)
- Form: Freeze‑dried (lyophilised) protein powder
- Documentation: Certificate of Analysis (COA) supplied with each lot
- Mechanism: Functions as a decoy receptor for ActRIIB, binding ligands such as myostatin (GDF‑8), activins, and other TGF‑β family proteins that negatively regulate muscle growth
Protein Information
- Structure: Fusion of the extracellular domain of human ActRIIB with the Fc portion of human IgG1
- Classification: Recombinant fusion protein for research workflows
- Myostatin inhibition studies
- Muscle wasting and sarcopenia models
- Duchenne muscular dystrophy (DMD) research
Storage & Stability
- Long‑term: –20 °C, dry and desiccated
- Short‑term: Stable at 2–8 °C
- Handling Note: Avoid repeated freeze–thaw cycles
Intended Use
- For laboratory research only
- Not for human or veterinary use
- Not approved for diagnostic, therapeutic, or medical applications
- Must be handled using appropriate laboratory safety practices
Why Choose ACE‑031?
- Unique mechanism targeting myostatin and activin pathways
- High purity suitable for sensitive experimental systems
- Full batch traceability with COA included
- Lyophilised for extended stability
| Weight | 100 g |
|---|---|
| Dimensions | 1 × 1 × 3 cm |
